Search Results - "Alhadab, Ali"

Increased Antifungal Drug Resistance in Clinical Isolates of Cryptococcus neoformans in Uganda by Smith, Kyle D, Achan, Beatrice, Hullsiek, Kathy Huppler, McDonald, Tami R, Okagaki, Laura H, Alhadab, Ali A, Akampurira, Andrew, Rhein, Joshua R, Meya, David B, Boulware, David R, Nielsen, Kirsten

“…Cryptococcal antigen screening is recommended among people living with AIDS when entering HIV care with a CD4 count of <100 cells/μl, and preemptive…”
Get full text

Population Pharmacokinetics of Sertraline in Healthy Subjects: a Model-Based Meta-analysis by Alhadab, Ali A., Brundage, Richard C.

“…Sertraline pharmacokinetics is poorly understood and highly variable due to large between-subject variability with inconsistent reports for oral…”
Get full text

Physiologically‐Based Pharmacokinetic Model of Sertraline in Human to Predict Clinical Relevance of Concentrations at Target Tissues by Alhadab, Ali A., Brundage, Richard C.

“…Significant in vitro and in vivo evidence supports the potential use of sertraline as an anticancer and antimicrobial agent. Yet, it is unknown whether…”
Get full text

Amikacin Pharmacokinetic-Pharmacodynamic Analysis in Pediatric Cancer Patients by Alhadab, Ali A, Ahmed, Mariam A, Brundage, Richard C

“…We performed pharmacokinetic-pharmacodynamic (PK-PD) and simulation analyses to evaluate a standard amikacin dose of 15 mg/kg once daily in children with…”
Get full text

Efficacy of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis: an open-label dose-ranging study by Rhein, Joshua, Dr, Morawski, Bozena M, MPH, Hullsiek, Kathy Huppler, PhD, Nabeta, Henry W, MBChB, Kiggundu, Reuben, MBChB, Tugume, Lillian, MBChB, Musubire, Abdu, MMed, Akampurira, Andrew, BS, Smith, Kyle D, BS, Alhadab, Ali, PharmD, Williams, Darlisha A, MPH, Abassi, Mahsa, DO, Bahr, Nathan C, MD, Velamakanni, Sruti S, BS, Fisher, James, BS, Nielsen, Kirsten, PhD, Meya, David B, MMed, Boulware, David R, MD

“…Summary Background Cryptococcus is the most common cause of adult meningitis in Africa. We assessed the safety and microbiological efficacy of adjunctive…”
Get full text

Semimechanistic Modeling to Guide Venetoclax Coadministration with Ritonavir and Digoxin by Alhadab, Ali A., Salem, Ahmed Hamed, Freise, Kevin J.

“…Venetoclax is a cytochrome P450, family 3, subfamily A (CYP3A) substrate and was shown to inhibit P‐gp efflux transporters in vitro. To quantify the impact of…”
Get full text

Case–control matching‐guided exposure‐efficacy relationship for avelumab in patients with urothelial carcinoma by Soltantabar, Pooneh, Alhadab, Ali, Hibma, Jennifer, Roychoudhury, Satrajit, Wang, Diane D., Bello, Carlo, Elmeliegy, Mohamed

“…Exposure‐response (E‐R) analyses are an integral component of understanding the benefit/risk profile of novel oncology therapeutics. These analyses are…”
Get full text

Pharmacokinetics-pharmacodynamics of sertraline as an antifungal in HIV-infected Ugandans with cryptococcal meningitis by Alhadab, Ali A., Rhein, Joshua, Tugume, Lillian, Musubire, Abdu, Williams, Darlisha A., Abassi, Mahsa, Nicol, Melanie R., Meya, David B., Boulware, David R., Brundage, Richard C.

“…The ASTRO-CM dose-finding pilot study investigated the role of adjunctive sertraline for the treatment of HIV-associated cryptococcal meningitis in…”
Get full text

Global coinfections with bacteria, fungi, and respiratory viruses in children with SARS-CoV-2: A systematic review and meta-analysis by Alhumaid, Saad, Alabdulqader, Muneera, Al Dossary, Nourah, Al Alawi, Zainab, Alnaim, Abdulrahman A, Al Mutared, Koblan M, Al Noaim, Khalid, Al Ghamdi, Mohammed A, Albahrani, Suha Jafar, Alahmari, Abdulaziz A, Al Hajji Mohammed, Sarah Mahmoud, Almatawah, Yameen Ali, Bayameen, Omar Musa, Alismaeel, Ahmed Abdulwhab, Alzamil, Sherifah Khaled, Alturki, Samiah Ahmad, Albrahim, Zahra'a Radi, Al Bagshi, Nasreen Ahmad, Alshawareb, Hesham Yousef, Alhudar, Jaafar Abdullah, Algurairy, Qassim Abdulatif, Alghadeer, Samirah Mansour, Alhadab, Hassan Ali, Aljubran, Taleb Nasser, Alabdulaly, Yousif Ahmad, Al Mutair, Abbas, Rabaan, Ali A

“…Background: Coinfection with bacteria, fungi, and respiratory viruses has been described as a factor associated with more severe clinical outcomes in children…”
Get full text

Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations by Yang, Derek Z., Alhadab, Ali, Parivar, Kourosh, Wang, Diane D., Elmeliegy, Mohamed

“…Patients with cancer and advanced hepatic impairment (HI) (i.e., moderate and severe impairment) are often excluded from first‐in‐patient, phase II, and phase…”
Get full text

Subcutaneous amivantamab (ami) in patients (pts) with advanced solid malignancies: The PALOMA study—Updated safety and identification of the recommended phase 2 dose by Minchom, Anna Rachel, Krebs, Matthew G, Cho, Byoung Chul, Lee, Se-Hoon, Leighl, Natasha B., O'Neil, Bert, Sabari, Joshua K., Kudgus-Lokken, Rachel, Alhadab, Ali, Haddish-Berhane, Nahor, Zemlickis, Donna, Mitselos, Anna, Berkay, Eileen, Bauml, Joshua Michael, Knoblauch, Roland E., Hellemans, Peter, Johnson, Melissa Lynne

“…9126 Background: Ami, an EGFR-MET bispecific antibody, is approved for pts with advanced EGFR exon 20 insertion non-small cell lung cancer after progression on…”
Get full text

Subcutaneous versus Intravenous Amivantamab, both in Combination with Lazertinib, in Refractory EGFR -mutated NSCLC: Primary Results from the Phase 3 PALOMA-3 Study by Leighl, Natasha B, Akamatsu, Hiroaki, Lim, Sun Min, Cheng, Ying, Minchom, Anna R, Marmarelis, Melina E, Sanborn, Rachel E, Chih-Hsin Yang, James, Liu, Baogang, John, Thomas, Massutí, Bartomeu, Spira, Alexander I, Lee, Se-Hoon, Wang, Jialei, Li, Juan, Liu, Caigang, Novello, Silvia, Kondo, Masashi, Tamiya, Motohiro, Korbenfeld, Ernesto, Moskovitz, Mor, Han, Ji-Youn, Alexander, Mariam, Joshi, Rohit, Felip, Enriqueta, Voon, Pei Jye, Danchaivijitr, Pongwut, Hsu, Ping-Chih, Silva Melo Cruz, Felipe José, Wehler, Thomas, Greillier, Laurent, Teixeira, Encarnação, Nguyen, Danny, Sabari, Joshua K, Qin, Angel, Kowalski, Dariusz, Nahit Şendur, Mehmet Ali, Xie, John, Ghosh, Debopriya, Alhadab, Ali, Haddish-Berhane, Nahor, Clemens, Pamela L, Lorenzini, Patricia, Verheijen, Remy B, Gamil, Mohamed, Bauml, Joshua M, Baig, Mahadi, Passaro, Antonio

“…Phase 3 studies of intravenous amivantamab demonstrated efficacy across -mutated advanced non-small cell lung cancer (NSCLC). A subcutaneous formulation could…”
Get full text

The Utility of Pharmacometrics in Drug Development and Pharmacotherapy of Antimicrobials by Alhadab, Ali Ahmed

“…Infectious diseases are a growing major public health concern due to the increase of antimicrobial resistance to current therapies and the lack of new drugs in…”
Get full text